In future studies, the atherogenic properties of lipoprotein subclasses might be considered when employing antidiabetic DPP-4 inhibitors, especially in patients with type-2 diabetes who are at risk for ASCVD or who are undergoing statin treatment. Here, DPP4 is linked to type 2 diabetes mellitus.